Teva, Amgen Reach Settlement On Copies Of Neupogen, Neulasta

NEW YORK -(Dow Jones)- Teva Pharmaceutical Industries Ltd. (TEVA, TEVA.TV) and Amgen Inc. (AMGN) have reached a settlement agreement that would allow Teva to launch copycat versions of Neupogen and Neulasta, used to prevent infections in patients receiving chemotherapy, by November 2013 at the latest. Amgen reported $3.6 billion in U.S. sales of the two drugs last year...